and the new approval in RCC - the most common form of kidney cancer - will be a major component of that growth. Eisai's chief executive of US operations Ivan Cheung has described the drug as the ...

Patients are losing out on life-changing drugs for cancer and rare diseases because of Brexit, experts have warned.

Originally developed as an anti-cancer therapy, Cilengitide progressed through ... levels and identify individuals who could potentially benefit from this drug.” Beyond chronic kidney disease, the ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

The commonly used Cockcroft-Gault method may result in excessive chemotherapy dosing — with potentially dire implications.

About 85% of brand-name drugs prescribed in the U.S. rely on ... Overall survival in advanced/metastatic non-clear cell kidney cancer improved significantly with nivolumab (Opdivo) plus ipilimumab ...